• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Centogene N.V. (NQ: CNTG )

    0.3250 UNCHANGED
    Last Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.3250
    Bid (Size) 0.3500 (12)
    Ask (Size) 0.3730 (1)
    Prev. Close 0.3250
    Today's Range 0.3250 - 0.3250
    52wk Range 0.2511 - 1.345
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE Receives Delisting Notice From Nasdaq
    From Centogene NV
    Via GlobeNewswire

    Performance

    YTD
    -72.22%
    -72.22%
    1 Month
    N/A
    N/A
    3 Month
    +14.04%
    +14.04%
    6 Month
    -27.78%
    -27.78%
    1 Year
    -74.14%
    -74.14%

    More News

    Read More
    CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
    From Centogene NV
    Via GlobeNewswire
    C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
    From Centogene NV
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
    From Centogene NV
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    CENTOGENE Receives Nasdaq Non-Compliance Notice
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE Explores Strategic Alternatives
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE Receives French Research Tax Credit Accreditation
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE Announces Preliminary Full Year 2023 Revenue
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE Announces Voting Results of Extraordinary General Meeting
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
    From Centogene NV
    Via GlobeNewswire
    CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
    From Centogene NV
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.